Претраживање
Приказ резултата 1-10 од 15
Developmental and differential changes of gene expression in erythroid progenitor cells.
(Amer Soc Hematology, Washington, 2005)
Combined endothelin and AII blockade reduces mean arterial pressure and fails to improve postischaemic acute renal failure
(Lippincott Williams & Wilkins, Philadelphia, 2003)
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
(Amer Soc Hematology, Washington, 2006)
Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP ...
Influence of microenvironmental conditions on hybridoma cell growth inside the alginate-poly-L-lysine microcapsule
(Elsevier Sci Ltd, Oxford, 2007)
A mathematical model was formulated to describe hybridoma cell growth within the alginate-poly-L-lysine (alginate-PLL) microcapsules during air-lift bioreactor cultivation. Model development was based on experimentally ...
Globin genes induction by nitric oxide of stromal cell origin
(Amer Soc Hematology, Washington, 2007)
Haemodynamic effects of no and vitamin C supplementation in SHR with acute renal failure
(Lippincott Williams & Wilkins, Philadelphia, 2006)
Training and capacity building in central and eastern Europe through the EuroFIR and CEE networks
(Elsevier Sci Ltd, Oxford, 2009)
Capacity building in food and nutrition aims to enhance knowledge and support infrastructural development in this field. International Network of Food Data Systems (INFOODS) was established on the basis of the recommendations ...
Incidence of anti-alfa fodrin antibodies in primary sjogren syndrome and its correlation with anti ro/SS-A and anti La/SS-B antibodies
(BMJ Publishing Group, London, 2006)
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
(Amer Soc Hematology, Washington, 2008)
Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the ...
Serologic rebounds after one-year-long treatment for congenital toxoplasmosis
(Lippincott Williams & Wilkins, Philadelphia, 2000)